Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals

We are a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies. 

Learn more about Synergy

Our Team

We have GI expertise and a proven track record of execution.

Learn more about Synergy's team

Plecanatide

Plecanatide is our lead uroguanylin analog currently being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

Learn more about plecanatide
Go to News & Media

Latest News & Events

Our Pipeline

Proprietary GI Platform Based on Uroguanylin

Plecanatide is our first uroguanylin analog currently being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Dolcanatide is our second uroguanylin analog currently being explored for inflammatory bowel disease (IBD).

Learn more about our pipeline
Compound Indication Phase 1 Phase 2 Phase 3 NDA
Filing
Marketed
Plecanatide
(sp-304)
CIC
IBS-C
DOLCANATIDE
(sp-333)
OIC
UC
Go To Investor Relations

Investor Relations

Overview

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies.

Recent Documents

SGYP NASDAQ
Volume
Market Cap
Change